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Volume 59, Number 2 Abstracts 563and no statin use (HR, 3.41; P ¼ .006) at baseline. The rate of stroke
referable to contralateral progression was 5.6% (6 of 107).
Conclusions: Restenosis and contralateral carotid stenosis after CEA
progress signiﬁcantly after 5 years, with possible impact on surveillance stra-
tegies. Restenosis was not associated with closure technique. Statin use re-
duces new symptoms but not the rate of disease progression.
Fig. Freedom from restenosis and contralateral progression of
ICA stenosis following CEA.
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Objectives: Carotid endarterectomy (CEA) is currently performed by
various surgical specialties with varying outcomes. This study analyzes
different surgical practice patterns and their impact on perioperative stroke
and cost.
Methods: This is a retrospective analysis of prospectively collected
data of 1000 consecutive CEAs performed at our institution by three
different specialties: general surgeons (GS), cardiothoracic surgeons (CT),
and vascular surgeons (VS).
Results: A total of 474 CEAs were done by VS, 404 by CT, and
122 by GS.VS tended to operate more often on symptomatic patients
than CT and GS: 40% vs 23% and 31%, respectively (P < .0001). Preop-
erative workups were signiﬁcantly different between specialties: duplex ul-
trasound (DUS) only in 66%, 30%, and 18%; DUS and CTA in 27%, 35%,
and 29%; DUS and MRA in 6%, 35%, and 52% for VS, CT, and GS,
respectively (P < .001). The mean preoperative carotid stenosis was not
signiﬁcantly different between the specialties. The mean heparin dosage
was 5168, 7522, and 5331 units (P ¼ .0001), and protamine was used
in 0.2%, 19%, and 8% (P < .0001) for VS, CT, and GS, respectively. Post-
operative drains were used more often by VS; however, there was no as-
sociation between heparin dosage, protamine, and drain use and
postoperative bleeding. Patching was used in 99%, 93%, and 76% (P <
.0001) for VS, CT, and GS. Bovine pericardial patches were used more
often by CT, and ACUSEAL (Gore) patches were used more often by
VS (P < .0001). The perioperative stroke/death rates were 1.27% for
VS and 3.04% for CT and GS combined (P ¼ .055); and for asymptom-
atic patients, 0.7% for VS and 3.02% for CT and GS combined (P < .034).
Perioperative stroke rates for patients who had preoperative DUS only
were 0.88% vs 3.29% for patients who had extra imaging (computed to-
mography/magnetic resonance angiography; P ¼ .009); and for asymp-
tomatic patients, it was 0.94% vs 3.01% (P ¼ .05). When applying
hospital billing charges for preoperative imaging workups (cost of DUS
only vs DUS and other imaging), the VS practice pattern would have
saved $1180 per CEA over CT and GS practice patterns; a total savings
of $1,180,000 in this series.
Conclusions: CEA practice patterns differ between specialties.
Although the cost was higher for non-VS practices, the perioperative
stroke/death rate was somewhat higher. Therefore, educating physicians
who perform CEAs on cost-saving measures may be appropriate.A Propensity Score Matched Analysis of Asymptomatic Patients
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Li Wang, BS, Thomas Curran, MD, John C. McCallum, MD, Dominique
Buck, MD, Jeremy Darling, BA, Mark Wyers, MD, Raul J. Guzman, MD,
Allen Hamdan, MD, Elliot Chaikof, MD, PhD, Marc L.
Schermerhorn, MD. Beth Israel Deaconess Medical Center, Boston, Mass
Objectives: Carotid endarterectomy (CEA) and coronary artery
bypass grafting (CABG) may be combined to treat concomitant coronary
artery and carotid artery atherosclerotic disease. Previous reports on com-
bined CEA/CABG have shown wide variation in adverse event rates for
asymptomatic patients and have often been limited by small sample size
or lack of granularity, or both. We aim to compare stroke and death after
CEA/CABG with CEA or CABG alone in asymptomatic patients by using
the American College of Surgeons (ACS) National Surgical Quality
Improvement Program (NSQIP) database.
Methods: All patients undergoing CEA, CABG, or CEA/CABG
from 2005 to 2011 in the NSQIP database were identiﬁed. NSQIP-docu-
mented neurologic symptoms lack laterality and temporal detail for assign-
ment of positive current neurologic symptoms, whereas asymptomatic
patients are captured with excellent accuracy. Accordingly, only asymptom-
atic patients were analyzed. Propensity score matched groups of asymptom-
atic patients were based on age, sex, and American Society of
Anesthesiologists class 4. Analysis of variance, c2, and multivariable logistic
regression were used to compare stroke, death, and combined stroke/death
across procedures.
Results: We identiﬁed 47,667 patients: 42,474 CEA (89%), 5018
CABG (11%), and 175 CEA/CABG (<1%). Forty percent of all patients
had a history of neurologic symptoms and were omitted from consideration:
43% CEA, 12% CABG, and 28% CEA-CABG. Unmatched rates of stroke/
death in asymptomatic patients were 1.4% (CEA), 3.3% (CABG), and 6.7%
(CEA/CABG). Propensity score matching identiﬁed 1332 asymptomatic
patients: 606 CEA, 607 CABG, and 119 CEA/CABG. Stroke, death,
and stroke/death rates are compared across procedures in the Table. In-
dependent risk factors for stroke/death among matched asymptomatic
patients were recent myocardial infarction (odds ratio [OR], 4.0; 95%
conﬁdence interval [CI], 2.0-8.0), COPD (OR, 4.7l; 95% CI, 2.4-9.2), and
age >70 years (OR, 2.7; 95% CI, 1.4-5.2). CEA/CABG compared with
CABG alone did not have increased risk of stroke/death (OR, 6; 95% CI,
0.2-1.4). No signiﬁcant difference was seen between the stroke/death rate
of CEA/CABG (6.7%) compared with the aggregate of CEA and CABG
alone (2.1% + 4.2%).
Conclusions: In asymptomatic patients, CEA/CABG does not
confer an increased risk for stroke/death compared with the combined
risk of CEA and CABG alone. CEA/CABG should be considered a safe
approach in asymptomatic patients requiring CEA and CABG.
Table. Propensity score matched group outcome comparison
CEA CABG CEA-CABG PVariable (n ¼ 606) (n ¼ 607) (n ¼ 119) (CABG vs CEA/CABG)Death, % 1.2 2.3 3.4 .516
Stroke, % 1.2 2.0 3.4 .314
Stroke/
death, %
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Objectives: Long-term hemodialysis patients are a difﬁcult patient
population because they have few remaining access options and may have
disadvantaged vasculature in the upper extremities. Because of the increased
infection rate with femoral access, surgeons may place an axillary artery-to-
axillary vein arteriovenous graft (AAAVg). Few outcome reports of this
technique exist. In this study, which is the largest reported to date, we inves-
tigate the results of the AAAVg conﬁguration.
Methods: At our institution, an AAAVg is a polytetraﬂuoroethylene
(PTFE) graft in a loop conﬁguration in the upper chest with anastomoses
to the axillary artery and ipsilateral axillary vein. After Investigational Review
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spectively identiﬁed and followed up for a 2-year period.
Results: Sixty-three AAAVgs were reviewed. Patient were an average
age of 55 years (range, 23-85 years), and 93% had documented prior access.
Thirty-eight patients required graft interventions in the follow-up period.
Twenty-one balloon angioplasties were performed for outﬂow venous ste-
nosis. Fourteen grafts thrombosed at an average of 461 days after implant.
Seven patients had bacteremia resulting in four graft removals (6%) as the
infective source. Two wound complications (one hematoma, one superﬁcial
wound dehiscence) occurred, but the graft was preserved. Notably, no pa-
tient required treatment for steal. The average primary patency rate was 85%
at 30 days, 51% at 6 months, and 33% at 1 year. Primary assisted patency was
90% at 6 months, 79% at 1 year, and 37% at 2 years. Secondary patency was
92% at 6 months and 58% at 1 year. Twenty-one patients required a new
access at an average of 477 days after the initial placement. Since receiving
their grafts, 25 of the 63 patients have died, and one patient received a
transplant.
Conclusions: AAAVgs are appropriate for patients who have few up-
per extremity access options. The patency rates for this “bailout” procedure
are at least equivalent to other upper extremity AV grafts. The lack of symp-
tomatic steal is an important beneﬁt. The infection rate is lower than in
femoral grafts, and correspondingly, AAAVgs can even be considered for
primary use in patients that have disadvantaged upper extremity vasculature
or who are at increased risk of steal syndrome.
Patient Compliance Limits the Efforts of Quality Improvement
Initiatives on Arteriovenous Fistula Maturation
Susanna K. Lynch, BS, Sadaf S. Ahanchi, MD, David J. Dexter, MD, Marc
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Objectives: Our institutional quality improvement (QI) initiative
monitors the schedule for arteriovenous ﬁstula (AVF) maturation with
follow-up #30 days after creation, ﬁstulogram #40 days if indicated, and
a second ofﬁce visit #8 weeks. Additionally, a patient liaison contacts pa-
tients and dialysis units in cases of delayed follow-up. The purpose of this
study is to determine the impact of the QI initiative on patient compliance
and overall time to AVF maturation.
Methods: We performed a retrospective review of patients undergo-
ing initial radiocephalic (RC), brachiocephalic (BC), and basilic vein trans-
position (BVT) creation before the QI initiative (pre-QI group: January to
April 2012) and during the QI period (QI group: January to April 2013).
Categoric data were compared using c2 analysis, and nominal data were
compared using the Student t-test.
Results: We reviewed 198 ﬁrst-time AVF creations in patients (57%
male) with a mean age of 61 years. Demographics and comorbidities be-
tween the pre-QI and QI groups were similar. During the pre-QI period,
110 initial AVFs were created: 28% RC, 44% BC, and 28% BVT, whereas
during the QI period, 88 initial AVFs were created: 27% RC, 51% BC,
and 22% BVT (c2 ¼ 0.487). Compliance with the 30-day postoperative
appointment increased signiﬁcantly after the QI initiative, from 48% in
the pre-QI group to 65% in the QI group (P ¼ .015). Yet, the QI initiative
did not maintain an impact on the subsequent follow-up checkpoints. No
statistical difference was identiﬁed for compliance with ﬁstulogram #40
days of access creation (pre-QI: 12% vs QI: 25%; P ¼ .093) and for compli-
ance with the 8-week postoperative appointment (pre-QI: 33% vs QI: 23%;
P ¼ .457). Both checkpoints demonstrated a very high noncompliance rate.
Accordingly, time to maturation was 88 days for both the pre-QI and QI
group, with a failure to mature rate of 22% for the pre-QI group and 21%
for the QI group.
Conclusions: The QI initiative signiﬁcantly increased the number of
patients complying with the ﬁrst 30-day follow-up appointment after access
creation. However, patient compliance with a timely ﬁstulogram and the
second follow-up appointment was very poor and not inﬂuenced by the
QI initiative, limiting the functional impact of the QI initiative on time to
AVF maturation.
Outcomes of Percutaneous Suture-Mediated Vessel Closure in Venous
Interventions
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Objectives: The safety and efﬁcacy of vascular closure devices in the
arterial system has been well documented. However, there are no reports
describing the use of these devices in the venous system, despite the
increasing frequency of percutaneous venous interventions, often involving
large-bore sheaths in anticoagulated patients. This report describes our
experience using the Perclose ProGlide (Abbott Vascular Devices, Pleasan-
ton, Calif) suture-mediated device in venous closure.Methods: A retrospective review of all patients undergoing off-label
venous access closure with the Perclose was performed from 2008 to
2012. Seventy patients (50% male; mean age, 28 years) underwent 70
femoral venous access closures for sheaths ranging from 9F to 22F (mean,
18F). A single Perclose device was used postintervention for sheaths up to
12F, and two Perclose devices were used with the “Perclose” technique
for sheaths >12F. Indications for intervention included nonthrombotic
May-Thurner syndrome with leg swelling, May-Thurner syndrome with
deep vein thrombosis, and pulmonary insufﬁciency requiring a percutaneous
pulmonic valve. All patients underwent full anticoagulation intraprocedur-
ally (activated clotting time >250 seconds) and at the time of vessel access
closure. Mean follow-up was 13 months, and consisted of a physical exam-
ination (all patients) and venous duplex ultrasound imaging (20%). Main
outcome measures were deep venous thrombosis (DVT) and access site
hematoma.
Results: During longitudinal follow-up, there were no documented
cases of DVT or access site hematoma. Venous duplex ultrasound imaging
was performed between 1 and 56 months postprocedurally, with normal
ﬂow documented in all studied patients. Six patients (9%) had ipsilateral
leg swelling necessitating imaging that demonstrated no evidence of DVT
or venous stenosis. Two deaths occurred (one <30 days, one late) due to
heart failure in pulmonary insufﬁciency patients, but neither was procedur-
ally related.
Conclusions: The use of suture-mediated devices in the venous sys-
tem appears to be well tolerated, with no documented cases of DVT in
our series. The absence of any occurrences of hematoma in these patients,
despite large-bore sheath access and full anticoagulation, suggests a clinical
beneﬁt for use of suture-mediated closure devices. Prospective studies with
routine duplex imaging after Perclose use in the venous system will better
elucidate the long-term safety of this technique.
United States National Survey of Vascular Surgery Consent
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Objectives: Currently, there are no explicit guidelines for informed
consent for vascular surgical interventions. Unfortunately, there is evidence
to suggest that consent deﬁciencies occur. The objective of this survey was
to catalog current peer practice and collate consensus relating to vascular
surgery patient consent.
Methods: A prospective anonymous online survey was adminis-
tered using Survey Monkey to members of the Society for Clinical
Vascular Surgery in June 2013. After completion of provider demo-
graphic details, each member evaluated general and procedural-speciﬁc
complications for arterial and venous interventions that should be dis-
cussed with patients during the informed consent process. Greater
than 75% reporting for a speciﬁc complication was deemed the threshold
for consensus opinion.
Results: Of 1210 members, 179 (14.8%) completed the survey. The
majority of respondents were staff surgeons (85.5%), followed by vascular
fellows (11.2%). Both groups considered vascular fellows competent to
obtain consent. The majority of patients were consented primarily by the
staff surgeons (67.6%) #24 hours of surgery (43%). This was done in the
outpatient (67.4%) or preoperative holding areas (66%). A procedure-spe-
ciﬁc, preprinted consent form was used in 95% of patients, with additional
written documentation provided in 59.7%. General complications discussed
before arterial surgery included bleeding (94.9%), cardiac (94.9%), cerebro-
vascular (92.6%), wound infection (90.4%), respiratory (78.7%), and throm-
boembolic (76%) events. Although respondents provided consent consensus
for a number of core vascular procedures, in patients undergoing open
aortic surgery, 10.2%, 14.4%, and 13.6% reported no discussion of bleeding,
impotence, or lower limb ischemia, respectively. Endoleak (5.6%), follow-up
surveillance (14.0%), graft occlusion/lower limb ischemia (8.4%), and rein-
tervention possibilities (10.3%) were additionally not documented during
EVAR consent by survey respondents. Surprisingly, cranial nerve injury
and restenosis were not discussed by 6.5% and 18.7% of vascular surgeons
performing carotid endarterectomy. For patients undergoing limb bypass
procedures, graft occlusion, limb loss, edema, and procedural failure were
not discussed in 5% to 9.9% of cases. General complications described dur-
ing venous procedures included bruising (90%), bleeding (86%), thrombo-
embolic events (87%), and wound infections (81.8%). However, nerve
injury, failure to improve symptoms, scarring, and recurrence were omitted
from discussion by 17.7%, 11.5%, 22.2%, and 12.5%, of respondents. Only
37% and 5.8% of vascular centers provided informal and formal consent
training, respectively.
Conclusions: The informed consent process presently used by most
providers is nonstandardized and inadequate. Recognized complications
for procedures are frequently not discussed during the informed consent
